Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
about
Recent advances of novel targeted therapy in non-small cell lung cancerEGFR targeted therapy in non-small cell lung cancer: potential role of cetuximabOptimizing the management of advanced non-small-cell lung cancer: a personal viewNon-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Single-Cell Sequencing Technology in Oncology: Applications for Clinical Therapies and ResearchA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesIs there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularK-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValueEGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidenceSecond-Line Therapy for Advanced NSCLCThe role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancerPromising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLCClonal evolution in hematological malignancies and therapeutic implicationsPooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clonesEGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.A perspective on anti-EGFR therapies targeting triple-negative breast cancerKRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsPharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyondPromising targets and current clinical trials in metastatic squamous cell lung cancerInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaReinventing diagnostics for personalized therapy in oncologyA trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancerFocal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung CancerPredictive and prognostic molecular markers for cancer medicineIntegrative computational biology for cancer researchComprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies.Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.Advances in diagnostic bronchoscopyPhase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics.Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer.A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.
P2860
Q21092930-0448AC98-A833-43E8-B280-B91E1FB67D55Q24652337-51883BCE-0CDC-405D-A58A-DE42080992E1Q24656144-A237D290-08CE-48A1-AD38-9D38E2DE9940Q26741814-982853EB-0982-4EDB-8BA6-AA77A759ABDEQ26744582-B014DA0C-7C7C-4066-8DC4-3E99D31049F4Q26797297-94A1D2EE-765D-4471-87D8-7718D364A99FQ26798882-BE2C8E5B-94A1-45E6-90C8-B9212A992E1DQ26828860-B49519FB-BD6B-4F4E-A355-7171EC5FCF9FQ26829425-66641920-53D1-4835-922F-81DB7E0ED340Q26853071-AB9C9FC9-6B83-49BF-8A64-30426D030536Q27002398-5FFE7D70-3C27-46D0-ABD8-1B54B278A3A8Q27021738-CBDDD691-78F8-4640-B5F1-F9181E42738AQ27025970-5C385366-C724-4FFF-AE9D-114B8BF1463CQ27027655-C27671B5-B548-420F-857B-9C40305A4286Q27313799-0B78EF5D-B1FE-4823-ACFB-CDE6527FD94DQ27851527-5D3FB5CC-99BD-426B-AFDD-6755D5CEF43BQ27851583-9739DCD9-9E4B-426F-9F34-4E0A0173966FQ27851860-817AC71B-A552-4DC4-B010-8D4C49EC8E77Q27852235-F927A31B-E29B-45BE-8ED1-DE33A2F4BB10Q28069867-C9AB8F66-E6AB-43B3-BE7E-30D958A15421Q28077570-1DB10DE0-6F5B-439F-9682-2B6B3D7A5F13Q28080730-A95B2D02-2797-4313-8D86-7ABBB6980ABEQ28083663-3D813572-E4CE-46D3-A130-DEE76D8F595BQ28303718-0721DED3-9251-4C05-A26A-8AE833772AD1Q28391395-5750918D-C270-4105-81DA-5A4010300CB4Q28487847-33007B1B-4A99-4B88-976C-21A42ACA463EQ28550689-D036EB2D-7EB8-47AC-B25E-C9C05732BF2DQ28743108-8161A8DC-94D9-4DDD-89E3-69790134C42FQ28744621-F8DEAACA-459B-4C97-A6FF-6C7E1A09480BQ30235944-FD020D6B-23B9-480E-BC39-585FF017F682Q30498101-0C61DB59-D219-4013-A391-3CFB1208526EQ30503596-F68F1013-44EF-4776-A15C-2ED453B90B57Q33161299-8ECA04A2-0479-4A0E-A503-2603D7AA40F6Q33407582-023EB0DF-827B-4337-B58C-D473F385EA5FQ33428782-797F87B9-10EB-4C3E-9EC2-DD851F16DD59Q33436643-3014BF3E-A87D-4BCF-B42D-5284DF666408Q33514878-49A0FAF9-451F-46D2-A265-C7B867E67C60Q33520794-8105F85D-8FB4-480E-9465-8B815093F25CQ33561563-FB3B75EF-D9B4-4469-B9EE-746979EE19F6Q33618157-10210D44-09B5-431C-BD59-717F52C12EDC
P2860
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Role of KRAS and EGFR as bioma ...... ical Trials Group Study BR.21.
@en
Role of KRAS and EGFR as bioma ...... ical Trials Group Study BR.21.
@nl
type
label
Role of KRAS and EGFR as bioma ...... ical Trials Group Study BR.21.
@en
Role of KRAS and EGFR as bioma ...... ical Trials Group Study BR.21.
@nl
prefLabel
Role of KRAS and EGFR as bioma ...... ical Trials Group Study BR.21.
@en
Role of KRAS and EGFR as bioma ...... ical Trials Group Study BR.21.
@nl
P2093
P50
P356
P1476
Role of KRAS and EGFR as bioma ...... ical Trials Group Study BR.21.
@en
P2093
Akira Sakurada
Chang-Qi Zhu
Frances A Shepherd
Jean-Claude Cutz
Keyue Ding
Lesley Seymour
Marlo Whitehead
National Cancer Institute of Canada Clinical Trials Group Study BR.21
Paula Marrano
P304
P356
10.1200/JCO.2007.14.8924
P407
P577
2008-07-14T00:00:00Z